Search Results for: Prima terapia farmacologica per l’apnea notturna (OSAS)

Stroke, Volume 56, Issue Suppl_1, Page AWP266-AWP266, February 1, 2025. Background:Sleep apnea symptoms, such as snoring and breathing pauses, often co-occur with depression in stroke survivors, adversely affecting recovery and quality of life. This study examines the relationship between the frequency of these symptoms and depression in stroke survivors.Methods:Data were analyzed from 737 stroke survivors enrolled in the Stroke Transitions Education and Prevention (STEP) clinic from January 2021 to August 2023. Sleep apnea symptoms were assessed using a modified questionnaire that emphasized frequent symptoms such as snoring, breathing pauses, being severely overweight, morning headaches, dry mouth, and gasping arousals. The presence of these symptoms contributed to coding participants as “Yes” for sleep apnea. Data were collected from patients seen over telemedicine or through electronic form submissions. Patients who opted out of participation in the registry were excluded from the analysis. Depression was measured using the Patient Health Questionnaire-9 (PHQ-9) and coded as binary: “Yes” for a PHQ-9 score ≥5 (mild to severe depression) and “No” for a score

90% di quelli estremamente pretermine sottoposto a cure dolorose

Introduction
Propofol is a fast-acting intravenous anaesthetic widely used for sedation and anaesthesia in gastrointestinal endoscopy, bronchoscopy, and the induction/maintenance of general anaesthesia in outpatients and inpatients; however, propofol has several undesirable effects, including injection pain, which affects the physical and mental health of patients, and cardiopulmonary depression, characterised by hypotension, bradycardia and apnea, which commonly occur in clinical practice. Ciprofol (HSK3486) is a propofol analogue with good clinical safety, high potency and some advantages over propofol, including lower injection pain and haemodynamic depression in patients undergoing gastroscopy and colonoscopy. This study aims to compare the impact of equivalent effective doses of propofol and ciprofol on haemodynamic changes in patients undergoing bronchoscopy under general anaesthesia.

Methods
This prospective, double-blind, randomised, controlled clinical trial will recruit 250 patients aged 18–80 years scheduled for elective bronchoscopy under general anaesthesia. The cohort will be randomised into two groups in a 1:1 ratio: propofol (200 mg/20 mL of saline) and ciprofol (40 mg/20 mL of saline). The primary outcomes are changes in heart rate and blood pressure before and after induction, laryngeal mask airway (LMA) placement and bronchoscopy placement. The secondary outcomes are the incidence of choking and injection pain, the type and dose of vasoactive drugs used during the operation, and the level of postoperative satisfaction among surgeons, anaesthesiologists and patients.

Ethics and dissemination
This trial was approved by the Medical Ethics Committee of Shanghai Fourth People’s Hospital, School of Medicine, Tongji University and registered with the Chinese Clinical Trials Registry (Identifier: ChiCTR2200063048) on 29 August 2022. The findings of this study will be disseminated through various channels. Academic dissemination will include publication in peer-reviewed journals and presentations at national and international conferences.

Trial registration number
ChiCTR2200063048.

Test avviati negli Usa. A Ferrara trattata una paziente, tra i primi centri in Europa

Il paziente ha 68 anni e ora si trova in terapia intensiva

Ricoverato il 60%, il 13,5 in terapia intensiva, mortalità 10,6%

Parte dall’Abruzzo ‘Respirare è un diritto di tutti’

L’opposizione critica sul mancato incarico al vicepresidente

Ma dovrà rimanere in terapia intensiva per 48 ore

Stabilizza vista e può ridurre necessità iniezioni intravitreali

Da biopsia liquida a studio cellule epatiche, per malattie rare

Efficace nel 30% dei pazienti che non risponde alle altre cure